OYSTER POINT MARINA PLAZA Seventh Amendment to Office LeaseOffice Lease • March 15th, 2005 • Titan Pharmaceuticals Inc • Biological products, (no disgnostic substances) • California
THIS SEVENTH AMENDMENT TO OFFICE LEASE (the “Seventh Amendment”) is made and entered into as of October 1, 2004, by and between KASHIWA FUDOSAN AMERICA, INC., a California corporation (“Landlord”) and TITAN PHARMACEUTICALS, INC., a Delaware corporation (“Tenant”).
MERGER AGREEMENTMerger Agreement • March 15th, 2005 • Titan Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
This Merger Agreement (this “Agreement”) is dated October 15, 2003 (the “Effective Date”), and is by and among Developmental Therapeutics, Inc., a company duly organized and existing under the laws of the State of Delaware, having a place of business located at 801 Brickell Avenue, Suite 942, Miami, Florida 33131 (hereinafter referred to as “DTI”), Titan Pharmaceuticals, Inc., a company duly organized and existing under the laws of the State of Delaware, having a place of business located at 400 Oyster Point Blvd., Suite 505, South San Francisco, CA 94080 (hereinafter referred to as “Titan”), Developmental Therapeutics Acquisition Corp., a company duly organized and existing under the laws of the State of Delaware, having a place of business located at 400 Oyster Point Blvd., Suite 505, South San Francisco, CA 94080 (hereinafter referred to “Acquisition Sub”), and Steve H. Kanzer and Nicholas Stergis (each a “Founder” and collectively, the “Founders”).
AMENDMENT TO EMPLOYMENT AGREEMENTEmployment Agreement • March 15th, 2005 • Titan Pharmaceuticals Inc • Biological products, (no disgnostic substances) • California
THIS AMENDMENT to the Employment Agreement dated February 1, 1993 (the “Employment Agreement”) between Titan Pharmaceuticals, Inc. (the “Company”) and Louis R. Bucalo, M. D. (the “CEO”) is made as of February 7, 2005. Capitalized terms used in this Amendment shall have the same meanings set forth in the Employment Agreement.
to DEVELOPMENT AND LICENSE AGREEMENT dated 25th January, 2000 between TITAN PHARMACEUTICALS, INC. and SCHERING AKTIENGESELLSCHAFTDevelopment and License Agreement • March 15th, 2005 • Titan Pharmaceuticals Inc • Biological products, (no disgnostic substances)
THIS ADDENDUM is made the 25th day of February 2004 (the “Effective Date”) between TITAN PHARMACEUTICALS, INC., a corporation organized and existing under the laws of the State of Delaware and having its principal place of business at 400 Oyster Point Boulevard, Suite 505, South San Francisco, California 94080 (“Titan”) and SCHERING AKTIENGESELLSCHAFT, a corporation organized and existing under the laws of Germany and having its principal place of business at Muellerstrasse 178, D-13342 Berlin, Germany (“Schering”).
